Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03882008 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis
A Phase 4 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT03882008 is a Phase 4 study that has completed, run by University of Washington. The registered enrollment target is 25 participants.
The verdict
NCT03882008, a Phase 4 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate if baseline levels of T cell associated biomarkers predict efficacy of abatacept during 24 weeks of treatment in patients with moderate to severe active Rheumatoid Arthritis (RA) who have had an inadequate response to conventional disease modifying anti-rheumatic drugs (cDMARDs)
Interventions
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03882008
The ClinicalTrials.gov registry entry for NCT03882008 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abatacept is the first listed.
NCT03882008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03882008 about?
NCT03882008 is a clinical study titled "A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis". The primary objective of this study is to evaluate if baseline levels of T cell associated biomarkers predict efficacy of abatacept during 24 weeks of treatment in patients with moderate to severe active Rheumatoid Arthritis (RA) who have had an inadequate response to conventional disease modifying ...
What is the current status of trial NCT03882008?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2019-05-23. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT03882008?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT03882008?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.